New pill shows promise for rare bile duct cancer in japanese patients
NCT ID NCT06081829
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study tests an oral drug called ivosidenib in 12 Japanese patients with advanced bile duct cancer that has a specific IDH1 gene mutation. Participants take the pill daily in 28-day cycles until the cancer worsens or side effects become too severe. The goal is to see if the drug can delay cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hokkaido University Hospital (JPN-006)
Sapporo, 060-8648, Japan
-
Kanagawa Cancer Center (JPN-003)
Yokohama, 241-8515, Japan
-
Kumamoto University Hospital (JPN-004)
Kumamoto, 860-8556, Japan
-
National Cancer Center Hospital (JPN-001)
Tokyo, Japan
-
National Cancer Center Hospital East (JPN-002)
Kashiwa, 277-8577, Japan
-
National Hospital Organization Shikoku Cancer Center (JPN-007)
Matsuyama, 791-0280, Japan
-
Osaka International Cancer Institute (JPN-005)
Osaka, 541-8567, Japan
Conditions
Explore the condition pages connected to this study.